Sign in

    Nabeel Nissar • Jefferies

    Nabeel Nissar is a Vice President and Senior Equity Research Associate at Jefferies, specializing in healthcare sector research. He covers leading pharmaceutical and biotechnology companies, providing in-depth analysis to institutional clients, though specific companies and performance metrics are not publicly documented. Nissar began his career in equity research before joining Jefferies, where he has been registered with FINRA (CRD#: 8004029), and holds active securities licenses as a regulated broker. His professional credentials and focus on healthcare research mark him as an emerging expert in the industry, contributing to Jefferies' robust analyst team.

    Nabeel Nissar's questions to CytomX Therapeutics Inc (CTMX) leadership

    Nabeel Nissar's questions to CytomX Therapeutics Inc (CTMX) leadership • Q2 2025

    Question

    Inquired about the strategy for creating value with the EpCAM target beyond colorectal cancer (CRC), including the role of partnerships and which other tumor types are being considered.

    Answer

    There is a significant opportunity to expand CX-2051 beyond CRC, as EpCAM is highly expressed in many solid tumors like lung, pancreatic, and breast cancer. However, the company's hands are full with the CRC opportunity, which is the immediate focus to build value. A partnership could be a future option for value creation, but the timing is not set.

    Ask Fintool Equity Research AI

    Nabeel Nissar's questions to CytomX Therapeutics Inc (CTMX) leadership • Q2 2025

    Question

    Nabeel Nissar from Jefferies asked about the strategy for creating value with the EpCAM target (CX-2051) in tumor types beyond colorectal cancer, including the potential role of partnerships.

    Answer

    Sean A. McCarthy, Chairman & CEO, acknowledged the enormous opportunity for CX-2051 outside of CRC, noting EpCAM's high expression in lung, pancreatic, and breast cancer. He suggested that a partnership could be beneficial for value creation in the future but emphasized that the company's near-term focus is to remain laser-focused on building value through the CRC opportunity first.

    Ask Fintool Equity Research AI